Genenta Science (NASDAQ:GNTA) Releases Earnings Results, Beats Expectations By $0.28 EPS

Genenta Science (NASDAQ:GNTA) issued its quarterly earnings results on Tuesday. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.28, FiscalAI reports.

Genenta Science Stock Performance

Genenta Science stock traded up $0.03 during mid-day trading on Wednesday, reaching $0.70. The company’s stock had a trading volume of 5,830 shares, compared to its average volume of 1,057,534. Genenta Science has a twelve month low of $0.59 and a twelve month high of $10.00. The business has a 50 day moving average price of $0.92 and a 200-day moving average price of $1.81.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of GNTA. Citadel Advisors LLC bought a new position in Genenta Science in the third quarter worth about $41,000. SmartHarvest Portfolios LLC acquired a new position in Genenta Science in the fourth quarter valued at approximately $26,000. Alyeska Investment Group L.P. bought a new position in shares of Genenta Science during the fourth quarter valued at approximately $328,000. Norges Bank acquired a new stake in shares of Genenta Science during the 4th quarter worth approximately $337,000. Finally, Weiss Asset Management LP bought a new stake in shares of Genenta Science in the 4th quarter worth approximately $480,000. 15.13% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a report on Friday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.